To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
133
ESTRATEST® administered orally QD
Esterified estrogens 1.25 mg administered orally QD
Change from baseline in the total score of the Menopause Rating Scale (MRS)
Time frame: 12 weeks
Change from baseline in the domain and individual item scores of the MRS
Time frame: 12 weeks
Change from baseline in the domain scores of the MENQOL
Time frame: monthly for 3 months
Comparison of changes in hormone levels and correlation with changes in the MRS
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site 66
Huntsville, Alabama, United States
Site 57
Mobile, Alabama, United States
Site 46
Montgomery, Alabama, United States
Site 29
Phoenix, Arizona, United States
Site 15
Tucson, Arizona, United States
Site 3
Jonesboro, Arkansas, United States
Site 22
Little Rock, Arkansas, United States
Site 68
Carmichael, California, United States
Site 55
Encinitas, California, United States
Site 6
San Diego, California, United States
...and 68 more locations